Orchard Therapeutics is targeting disorders with no treatment option or where existing options leave significant management gaps. Orchard’s autologous ex vivo gene therapy uses a patient’s own blood stem cells to correct a genetic disorder. Stem cells are taken from the patient (step 1) and modified outside of the body (“ex vivo”) using a viral vector carrying a functioning copy of the missing or faulty gene (step 2). The gene-modified cells are then transplanted back into the body (step 3).
Graduated in 2017
Contact:
Website: www.orchard-tx.com/contact-usGraduated in 2017
Graduate Companies
- Active Membranes
- Adaptix
- Aneeve
- Aneuvo
- Appia Bio
- Avesta76 Therapeutics
- Bluefin Foods
- CarbonBuilt
- Carbonics
- Charlot Biosciences
- CBD Research Institute
- Cellmic
- Concrete.ai
- Craytex
- CytoLumina
- DARTS Sciences
- EarlyDx
- ElectroNucleics
- EP Dynamics
- FemtoDx
- Ferrologix
- Gradient Orthodontics
- Horizon PV
- Inspira
- Inston
- InvVax
- Kelvi
- Keyssa
- Kythera Biopharmaceuticals
- Librede
- Lucendi
- Lookin, Inc.
- Matrix Sensors, Inc.
- MAX BioPharma
- MediSens Wireless
- MicrobeDx
- MyoGene Bio
- Myst Therapeutics
- Nammi Therapeutics
- Nanoarmor, LLC.
- NanoClear
- NanoElectronic Imaging
- NanoH₂O
- Nanopixel Technologies
- National Institute of Cannabinoid Research (NICR)
- Nuvola Technology
- Octant
- Omega Biosystems
- Orchard Therapeutics
- Partillion Bioscience
- Polyradiant
- Qwixel Therapeutics
- Restore Technologies
- Sardona Therapeutics
- Scarless Laboratories
- SELFA
- Sixal
- Spectradyne
- Symphony Biosciences
- Tempo Therapeutics
- TrueCath
- U-Defi
- Valerion Therapeutics
- ViBo Health
- Vivibaba
- Westwood Bioscience
- Zenomics
- Back to Portfolio